- Home
- EMF vs SPRY Comparison
EMF vs SPRY Comparison
Compare EMF & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMF | SPRY |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.9M | 400.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EMF | SPRY |
|---|---|---|
| Price | $21.06 | $2.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 16.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $52.57 |
| Revenue Next Year | N/A | $45.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.12 | $3.35 |
| 52 Week High | $24.70 | $13.15 |
Technical Indicators
Market Signals| Indicator | EMF | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 35.37 | 24.13 |
| Support Level | $19.91 | N/A |
| Resistance Level | $22.97 | $4.55 |
| Average True Range (ATR) | 0.45 | 0.28 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 18.25 | 0.99 |
Price Performance
Historical ComparisonAbout EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.